BACKGROUND: Use of recombinant @entity1 @entity10120 combined with conventional cytotoxic therapy to treat @entity5 has been growing because of evidence of increased efficacy. However, whether antiangiogenic therapy combined with chemotherapy really benefits @entity1 with advanced @entity1149 ( @entity1149 ) remains unclear. OBJECTIVES: This study was conducted to evaluate the clinical efficacy and safety of rh- @entity10120 (Endostar) combined with chemotherapy in the treatment of NSCLC @entity1 . METHODS: We selected data from the Cochrane Library, EMBASE, Medline, SCI,CBM, CNKI, to obtain all clinical controlled trials, including the addition of endostar to chemotherapy in advanced NSCLC @entity1 . Fifteen trials with 1335 @entity1 were included according to the inclusion criteria. All were randomized controlled trials, and two trials were adequate in reporting randomization. Seventeen trials did not mention the blinding methods. RESULTS: Meta-analysis indicated that the NPE arm ( @entity1206 + @entity900 +Endostar) had a different response rate compared with NP( @entity1206 + @entity900 ) arm (OR2.16, 95%CI 1.57 to 2.99). The incidences of severe @entity1431 (OR0.94, 95%CI 0.66 to 1.32) and severe @entity882 (OR 1.00, 95%CI 0.64 to 1.57) and @entity1209 (OR 0.85, 95%CI 0.61 to 1.20) were similar in the two arms. The NPE plus radiotherapy (RT) arm had a similar response rate compared with NP plus RT arm (OR 2.39, 95%CI 0.99 to 5.79), as were the incidences of @entity1431 (OR0.83, 95%CI 0.35 to 1.94), @entity882 (OR 0.78, 95%CI 0.19 to 3.16) and @entity1208 (OR 1.00, 95%CI 0.40 to 2.49). CONCLUSIONS: Our results suggested that in the treatment of advanced NSCLC, endostar in combination with @entity902 -based chemotherapy could improve the response rate without obviously increasing side effects.

Endostar combined with chemotherapy versus chemotherapy alone for advanced XXXX : a meta-analysis.

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLCs', 'non-small cell lung cancers'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1206 :: ('MESH:C030852', 'Chemical') :: ['Vinorelbine'] @entity1208 :: ('MESH:D004935', 'Disease') :: ['radiation esophagitis'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity10120 :: ('80781', 'Gene') :: ['endostatin'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity1209 :: ('MESH:D020250', 'Disease') :: ['nausea and vomiting']
@entity1149 :: (MESH:D002289,Disease) :: ['NSCLCs']
